pharma · Acne Vulgaris · Pruritus · VYNE
VYNE Therapeutics
Vyne Therapeutics (Israel) is a pharma organization headquartered in Bridgewater, USA. It trades on NYSE under ticker VYNE. Primary therapeutic focus areas include Acne Vulgaris, Pruritus, Rosacea, Epidermolysis Bullosa,
520 U.S. Highway 22, Suite 204, Bridgewater, NJ 08807, US HQ
2003 Founded
47 Employees
Public company Type
VYNE · NYSE Ticker
Company details
- Status
- Public
- HQ
- 520 U.S. Highway 22, Suite 204, Bridgewater, NJ 08807, US
- Founded
- 2003
- Employees
- 47
- Programs
- 30
- Drugs
- 16
- Patents
- 7
FMX103 1.5%
Phase 3 · small molecule · Papulopustular Rosacea
FMX103 1.5% for Papulopustular Rosacea is a Phase 3 program (small_molecule) at VYNE Therapeutics with 1 ClinicalTrials.gov record(s).
Internal code FX2016-13
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- VYNE Therapeutics
- Phase
- Phase 3
- Modality
- small_molecule
- Indication
- Papulopustular Rosacea
- Status
- completed
- Trials
- 1